Pharsight

Trintellix is owned by Takeda Pharms Usa.

Trintellix contains Vortioxetine Hydrobromide.

Trintellix has a total of 11 drug patents out of which 1 drug patent has expired.

Expired drug patents of Trintellix are:

US8476279

Trintellix was authorised for market use on 30 September, 2013.

Trintellix is available in tablet;oral dosage forms.

Trintellix can be used as use of trintellix for the treatment of major depressive disorder (mdd) in adults, method of treating an affective disorder such as depression, use in the treatment of major depressive disorder to improve processing speed, an aspect of cognitive function, method of treating depression or major depressive disorder, use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment.

The generics of Trintellix are possible to be released after 21 March, 2032.

Application	Filing Date	Opposition Party	Legal Status
EP07764495A	2012-10-11	Sandoz AG	Patent maintained as amended

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7144884	TAKEDA PHARMS USA	Phenyl-piperazine derivatives as serotonin reuptake inhibitors	Jun, 2026 (3 years from now)
US8722684	TAKEDA PHARMS USA	1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment	Jun, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476279	TAKEDA PHARMS USA	Phenyl-piperazine derivatives as serotonin reuptake inhibitors	Oct, 2022 (8 months ago)
US9861630	TAKEDA PHARMS USA	1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment	Jun, 2027 (4 years from now)
US9125908	TAKEDA PHARMS USA	1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment	Jun, 2027 (4 years from now)
US9125909	TAKEDA PHARMS USA	1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment	Jun, 2027 (4 years from now)
US9125910	TAKEDA PHARMS USA	1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment	Jun, 2027 (4 years from now)
US8969355	TAKEDA PHARMS USA	1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment	Jun, 2027 (4 years from now)
US11458134	TAKEDA PHARMS USA	1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment	Jun, 2027 (4 years from now)
US9227946	TAKEDA PHARMS USA	1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment	Jun, 2027 (4 years from now)
US9278096	TAKEDA PHARMS USA	Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity	Mar, 2032 (8 years from now)

Do you want to check out TRINTELLIX patents from before 2022?

Exclusivity	Exclusivity Expiration
M (M)	Jan 22, 2024

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

Market Authorisation Date: 30 September, 2013

Treatment: Method of treating an affective disorder such as depression; Method of treating depression or major depressive disorder; Use in the treatment of major depressive disorder to improve processing speed, ...

Dosage: TABLET;ORAL